Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03824704
Other study ID # CO-338-097
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date August 23, 2019
Est. completion date August 24, 2020

Study information

Verified date June 2023
Source zr Pharma & GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer. Patients entering the following cohorts must have BRCA mutational status confirmed by a central lab: - Cohort A1: No BRCA mutation in tumor; high level of LOH (loss of heterozygosity) - Cohort A2: BRCA mutation in tumor


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date August 24, 2020
Est. primary completion date August 24, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility General Inclusion Criteria: - = 18 years of age - Adequate organ function - Life expectancy = 16 weeks - Women of childbearing potential must have a negative serum pregnancy test - High-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer - Received 1 or 2 prior regimens, including = 1 prior platinum-based therapy and have platinum-sensitive disease - Relapsed/progressive disease (confirmed by radiologic assessment) - Willing and able to have a biopsy of tumor at screening and after 4 weeks of treatment. - Measurable disease (RECIST v1.1)- Cohort A1 only - ECOG performance status of 0 to 1 General Exclusion Criteria - Active second malignancy - Central nervous system brain metastases - Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of myocarditis. - Active, known or suspected autoimmune disease (eg, autoimmune hepatitis). - Condition requiring systemic treatment with either corticosteroids - Prior treatment with a PARP inhibitor or immune checkpoint inhibitor. - Non-epithelial tumors (pure sarcomas) or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors. Mixed Mullerian tumors/carcinosarcomas are allowed.

Study Design


Intervention

Drug:
Rucaparib
Oral rucaparib will be administered twice daily
Nivolumab
IV nivolumab will be administered once every 4 weeks

Locations

Country Name City State
United States University of Vermont Medical Center Burlington Vermont
United States Community Cancer Institute Clovis California
United States Women's Cancer Care Covington Louisiana
United States Stephenson Cancer Center Oklahoma City Oklahoma
United States Memorial Health University Medical Center Savannah Georgia

Sponsors (3)

Lead Sponsor Collaborator
zr Pharma & GmbH Bristol-Myers Squibb, Foundation Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) by RECIST v1.1 as Assessed by the Investigator Objective response rate (ORR) is defined as the percentage of patients with a best confirmed response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as assessed by the investigator. From enrollment until disease progression (up to approximately 2 years)
Primary The Effect of Rucaparib on the Immune Microenvironment Change in expression of the immune marker PD-L1 pre and post-rucaparib treatment; Cohort A2 only From enrollment to primary completion of study (up to approximately 2 years)
Secondary ORR by RECIST v1.1 and Gynecological Cancer InterGroup (GCIG) Cancer Antigen 125 (CA-125 Criteria) Objective Response Rate (ORR) is defined as the percentage of patients with a best confirmed response of complete response (CR) or partial response (PR) by RECIST v1.1 as assessed by the investigator or a confirmed response per Gynecological Cancer InterGroup (GCIG) cancer antigen 125 (CA-125 criteria) For patients with measurable disease, every 8 weeks after the start of combination treatment for 3 years, then every 24 weeks thereafter until disease progression or up to 25 months. Study data collection expected to last for 2 years.
Secondary Progression-free Survival (PFS) Progression-Free Survival (PFS) is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST, as determined by the investigator or death due to any cause, whichever occurs first. From randomization until disease progression (up to approximately 2 years)
Secondary Duration of Response (DOR) Duration of response (DOR) for any confirmed RECIST CR or PR measured from the date of the first response until the first date that progressive disease (PD) is documented. For patients with measurable disease, every 12 weeks after the start of combination treatment for 3 years, then every 24 weeks thereafter until disease progression. Study data collection expected to last for 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03393884 - Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) Phase 1/Phase 2
Completed NCT04546373 - Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Active, not recruiting NCT05456685 - IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer Phase 2
Completed NCT01442051 - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Completed NCT02928549 - Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
Active, not recruiting NCT03648489 - Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Phase 2
Not yet recruiting NCT04983550 - Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC Phase 2
Completed NCT02480374 - Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer Phase 1
Completed NCT01899599 - PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Phase 2
Completed NCT03480750 - Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer Phase 1/Phase 2
Completed NCT01610206 - A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Phase 2
Completed NCT01031381 - Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Phase 2
Completed NCT01219777 - Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian Phase 1
Completed NCT00959582 - Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) Phase 1
Completed NCT00801320 - Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer N/A
Suspended NCT00753480 - A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Phase 1
Completed NCT00768144 - Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma Phase 2
Completed NCT00702299 - Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer Phase 1
Recruiting NCT02349958 - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Phase 2
Terminated NCT00418093 - Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma Phase 2